Floatz logo

her2bi-armed activated t cells

Malignant Ovarian Clear Cell Tumor

Barbara Ann Karmanos Cancer InstituteCell therapyPhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malignant Ovarian Clear Cell Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
National Cancer Institute (NCI)
Phase 2B
Epacadostat
National Cancer Institute (NCI)
Phase 2CCC
Sargramostim
Barbara Ann Karmanos Cancer Institute
Phase 1CC

Same molecule, other indications

her2bi-armed activated t cells is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
metastatic prostate carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
PSA ProgressionDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →